PD-L1 expression on tumor cells facilitates FDA-approved companion diagnostics for PD-1/PD-L1 inhibitors [1], and the abundance of PD-1+ T cells elicits a better clinical response [2, 3], indicating that the expression of target molecules is a critical determinant of the therapeutic response. The gene discussed is PDCD1; the disease is neoplasm.